志贺氏菌疫苗研发：寻找阻力最小的途径。
Shigella Vaccine Development: Finding the Path of Least Resistance.
作者信息
Chen Wilbur H, Kotloff Karen L
机构信息
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA.
出版信息
Clin Vaccine Immunol. 2016 Dec 5;23(12):904-907. doi: 10.1128/CVI.00444-16. Print 2016 Dec.
Abstract
Shigella spp. represent the second most common etiologic pathogen causing childhood diarrhea in developing countries. There are no licensed Shigella vaccines, and progress for such vaccines has been limited. In this issue of Clinical and Vaccine Immunology, Riddle and colleagues (M. S. Riddle, R. W. Kaminski, C. Di Paolo, C. K. Porter, R. L. Gutierrez, et al., Clin Vaccine Immunol 23:908-917, 2016, http://dx.doi.org/10.1128/CVI.00224-16) report results from a phase I study of a parenterally administered monovalent O-polysaccharide "bioconjugate" directed against Shigella flexneri 2a. Ultimately, the goal is to develop a broad-spectrum Shigella vaccine to address this public health concern. A parenteral Shigella vaccine capable of eliciting protection in children of developing countries would be an important tool to reach this goal.
摘要
志贺氏菌属是发展中国家引起儿童腹泻的第二大常见病原体。目前尚无已获许可的志贺氏菌疫苗，此类疫苗的研发进展有限。在本期《临床与疫苗免疫学》中，里德尔及其同事（M.S. 里德尔、R.W. 卡明斯基、C. 迪保罗、C.K. 波特、R.L. 古铁雷斯等人，《临床与疫苗免疫学》23:908 - 917，2016年，http://dx.doi.org/10.1128/CVI.00224 - 16）报告了一项针对弗氏志贺菌2a的单剂量注射用单价O - 多糖“生物偶联物”的I期研究结果。最终目标是研发一种广谱志贺氏菌疫苗，以解决这一公共卫生问题。一种能够在发展中国家儿童中引发保护作用的注射用志贺氏菌疫苗将是实现这一目标的重要工具。
相似文献
1
Shigella Vaccine Development: Finding the Path of Least Resistance.
Clin Vaccine Immunol. 2016 Dec 5;23(12):904-907. doi: 10.1128/CVI.00444-16. Print 2016 Dec.
2
Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
Clin Vaccine Immunol. 2016 Dec 5;23(12):908-917. doi: 10.1128/CVI.00224-16. Print 2016 Dec.
3
-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei.
mSphere. 2021 Aug 25;6(4):e0012221. doi: 10.1128/mSphere.00122-21. Epub 2021 Jul 14.
4
Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
Pediatr Infect Dis J. 2003 Aug;22(8):701-6. doi: 10.1097/01.inf.0000078156.03697.a5.
5
Shigellosis: the current status of vaccine development.
Curr Opin Infect Dis. 2008 Jun;21(3):313-8. doi: 10.1097/QCO.0b013e3282f88b92.
6
Outer Membrane Vesicles Derived from Serotype Typhimurium Can Deliver 2a O-Polysaccharide Antigen To Prevent 2a Infection in Mice.
Appl Environ Microbiol. 2021 Sep 10;87(19):e0096821. doi: 10.1128/AEM.00968-21.
7
Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
Vaccine. 2010 Mar 2;28(10):2231-2235. doi: 10.1016/j.vaccine.2009.12.050. Epub 2010 Jan 5.
8
Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Vaccine. 2006 Mar 20;24(13):2290-301. doi: 10.1016/j.vaccine.2005.11.040. Epub 2005 Dec 5.
9
Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.
Pathog Dis. 2016 Jul;74(5). doi: 10.1093/femspd/ftw034. Epub 2016 Apr 21.
10
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
EBioMedicine. 2021 Apr;66:103310. doi: 10.1016/j.ebiom.2021.103310. Epub 2021 Apr 13.
引用本文的文献
1
A Pentavalent LPS-Based Vaccine Candidate Is Safe and Immunogenic in Animal Models.
Vaccines (Basel). 2023 Feb 3;11(2):345. doi: 10.3390/vaccines11020345.
2
Immunization of Rabbits with a Quadrivalent Bioconjugate Vaccine Induces Functional Antibodies Reactive with Isolates from Kenya.
mSphere. 2022 Jun 29;7(3):e0102021. doi: 10.1128/msphere.01020-21. Epub 2022 May 25.
3
Identification and evaluation of novel vaccine candidates against Shigella flexneri through reverse vaccinology approach.
Appl Microbiol Biotechnol. 2021 Feb;105(3):1159-1173. doi: 10.1007/s00253-020-11054-4. Epub 2021 Jan 16.
4
Challenges of Developing Novel Vaccines With Particular Global Health Importance.
Front Immunol. 2020 Oct 14;11:517290. doi: 10.3389/fimmu.2020.517290. eCollection 2020.
5
Duration of Postdiarrheal Enteric Pathogen Carriage in Young Children in Low-resource Settings.
Clin Infect Dis. 2021 Jun 1;72(11):e806-e814. doi: 10.1093/cid/ciaa1528.
6
Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G.
mSphere. 2020 Sep 23;5(5):e00416-20. doi: 10.1128/mSphere.00416-20.
7
SipD and IpaD induce a cross-protection against Shigella and Salmonella infections.
PLoS Negl Trop Dis. 2020 May 28;14(5):e0008326. doi: 10.1371/journal.pntd.0008326. eCollection 2020 May.
8
Increasing the Affinity of an O-Antigen Polysaccharide Binding Site in Shigella flexneri Bacteriophage Sf6 Tailspike Protein.
Chemistry. 2020 Jun 5;26(32):7263-7273. doi: 10.1002/chem.202000495. Epub 2020 May 19.
9
Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate.
Glycobiology. 2019 Aug 20;29(9):669-680. doi: 10.1093/glycob/cwz044.
10
-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses.
Hum Vaccin Immunother. 2019;15(6):1317-1325. doi: 10.1080/21645515.2019.1594132. Epub 2019 Apr 19.
本文引用的文献
1
Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study.
Lancet. 2016 Sep 24;388(10051):1291-301. doi: 10.1016/S0140-6736(16)31529-X.
2
Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
Clin Vaccine Immunol. 2016 Dec 5;23(12):908-917. doi: 10.1128/CVI.00224-16. Print 2016 Dec.
3
South Asia as a Reservoir for the Global Spread of Ciprofloxacin-Resistant Shigella sonnei: A Cross-Sectional Study.
PLoS Med. 2016 Aug 2;13(8):e1002055. doi: 10.1371/journal.pmed.1002055. eCollection 2016 Aug.
4
Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea.
Clin Vaccine Immunol. 2016 Jul 5;23(7):610-7. doi: 10.1128/CVI.00205-16. Print 2016 Jul.
5
Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults.
Clin Vaccine Immunol. 2016 Jul 5;23(7):564-75. doi: 10.1128/CVI.00665-15. Print 2016 Jul.
6
Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses.
Clin Vaccine Immunol. 2016 Jun 6;23(6):438-441. doi: 10.1128/CVI.00214-16. Print 2016 Jun.
7
Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.
Pathog Dis. 2016 Jul;74(5). doi: 10.1093/femspd/ftw034. Epub 2016 Apr 21.
8
Status of vaccine research and development for Shigella.
Vaccine. 2016 Jun 3;34(26):2887-2894. doi: 10.1016/j.vaccine.2016.02.075. Epub 2016 Mar 12.
9
Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.
Clin Vaccine Immunol. 2016 Apr 4;23(4):315-25. doi: 10.1128/CVI.00608-15. Print 2016 Apr.
10
Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli.
Glycobiology. 2016 Jan;26(1):51-62. doi: 10.1093/glycob/cwv077. Epub 2015 Sep 9.
Zotero 插件